
Zain Bahrain's H1 revenue hits $109mln; net profit up 4.8%
Announcing its financial results for the six months ended June 30, 2025, Zain Bahrain said basic and diluted earnings per share for H1 2025 remained stable at 7 fils. Ebitda for H1 fell by 5.9% to BD11.09 million from BD11.79 million for the same period in 2024.
Zain Bahrain's balance sheetremains strong with a total equity of BD 87.19 million as of June 30, 2025, compared to BD88.12 million for the year ended 31 December 2024, a slight decrease of 1.1%.
The company's asset base stood at BD133.32 million as of June 30, 2025, a reduction of 6.1% from BD 141.91 million as of December 31, 2024.
On its second quarter results, Zain Bahrain said its total profit attributable to the shareholders for the three- month period ended June 30, 2025 stood at BD1.37 million, representing an increase of 1% from BD1.35 million in Q2 2024. Basic and diluted earnings per share remained stable at 4 fils.
The revenue for Q2 increased to BD20.24 million representing a growth of 6.9% compared to BD18.93 million in Q2 2024. Ebitda for Q2 2025 decreased by 6.3% reaching BD 5.71 million from BD 6.09 million in Q2 2024.
Commenting on the results, Zain Bahrain Chairman Shaikh Ahmed bin Ali Al Khalifa said: "As we mark the midpoint of 2025, I am proud to share with you Zain's initiatives and results progress, which has strengthened our position as a national leader in innovation, youth empowerment, and customer experience."
"We have achieved a remarkable growth with strong performance across all key indicators, including revenue, net income, and customer base. This impressive performance is a direct result of the company's forward-thinking strategy and relentless commitment to drive innovation, enabling a prosperous digital future for its customers," he noted.
Shaikh Ahmed said: "Turning to our digital transformation journey, we have made significant advancements in our digital services and business operations by integrating AI solutions across many of our operational units, enhancing efficiency, and driving more informed decision-making."
"Additionally, Zain Bahrain continues to broaden its portfolio of offerings, solutions, and partnerships for its enterprise customers, enabling the company to secure multiple major ICT deals and deliver cutting-edge connectivity solutions," he stated.
"It is also noteworthy to reiterate that we have recently updated Zain Building design to create a more inclusive and diverse workplace environment that supports the varied needs and abilities of our employees and visitors which comes as part of Zain Bahrain's commitment to accessibility and inclusion," he noted.
The top official pointed out that its innovative microfinance solutions app, Bede, continues to thrive and break new ground by expanding its services to new customer segments and enhancing its app experience, enabling customers to obtain funding from Bede within minutes.
"As we conclude the first half of the year, we look to the future with great optimism and pride in the remarkable achievements we have accomplished," observed Shaikh Ahmed.
"These milestones reaffirm our commitment to continuous development, excellence in performance, and innovation. Zain Bahrain will remain steadfast in its strategy of fostering a culture of ongoing growth while delivering a future-focused, exceptional experience that empowers our customers at every step and supports the Kingdom's sustainable and inclusive digital transformation," he added.
Copyright 2024 Al Hilal Publishing and Marketing Group Provided by SyndiGate Media Inc. (Syndigate.info).
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Khaleej Times
27 minutes ago
- Khaleej Times
UAE Central Bank revokes licence of Al Nahdi Exchange
The Central Bank of the UAE (CBUAE) has revoked the licence of Al Nahdi Exchange, an Exchange House operating in the UAE, and struck its name off the Register, pursuant to Article (137) of the Decretal Federal Law No. (14) of 2018 Regarding the Central Bank and Organisation of Financial Institutions and Activities, and its amendments. The licence revocation was based on the CBUAE's examination findings, which revealed significant failures by the Exchange House to comply with the Anti-Money Laundering, Combating the Financing of Terrorism and Illegal Organisations, and Sanctions framework. The CBUAE, through its supervisory and regulatory mandates, endeavours to ensure that all exchange houses, their owners, and staff comply with the UAE laws, regulations and standards established by the CBUAE to maintain transparency and integrity of the exchange houses industry and safeguard the UAE financial ecosystem.


Zawya
27 minutes ago
- Zawya
New agreement brings breakthrough dyslipidemia treatment to Saudi Arabia and MEA
JEDDAH – Jamjoom Pharma, a leading Saudi pharmaceutical organization committed to enhancing the quality of life through the development, manufacturing, and distribution of high-quality medicines and consumer healthcare products across MEA, and Althera Laboratories, a company dedicated to developing and commercializing innovative therapies for cardiovascular and metabolic diseases, today announced a strategic licensing and supply agreement. This agreement is poised to address the growing need for effective dyslipidemia management in the region, contributing to better patient outcomes and cardiovascular health. Under this agreement, Jamjoom Pharma gets exclusive rights to commercialize in Saudi Arabia and non-exclusive rights for phased expansion across other MEA markets for Althera's fixed-dose combination of dual-action cholesterol-lowering therapy. The product launch in Saudi Arabia is targeted for 2027, with plans for phased expansion across MEA markets, subject to local regulatory approvals. This collaboration marks a major milestone for both companies: Jamjoom strengthens its cardiovascular portfolio with a globally recognized and clinically effective therapy, while Althera expands its international footprint in a high-growth region. The partnership aims to address the region's growing burden of cardiovascular diseases by increasing access to modern, affordable lipid-lowering treatment, to support patients across MEA. Dr. Tarek Hosni, CEO of Jamjoom Pharma, highlighted that: 'Cardiovascular diseases remain to be a leading health concern in Saudi Arabia and the wider MEA region, and this partnership enables us to provide patients across the MEA region with an innovative, evidence-based solution. Expanding access to effective cholesterol management aligns perfectly with our promise to deliver high-quality, affordable medications that improve lives.' Sanjeev Agarwal, CEO of Althera added " This partnership with Jamjoom Pharma is a pivotal step for Althera, allowing us to extend our reach into the rapidly growing MENA region. We are confident that Jamjoom's deep market understanding and robust capabilities make them the perfect partner to deliver our Rproduct to healthcare providers and patients in Saudi Arabia and across MENA. This collaboration is a testament to our dedication to making innovative and affordable cardiovascular treatments more accessible globally." About Althera: Founded in 2010, Althera focuses on developing, out-licensing, manufacturing and supplying high value branded and select complex generic medicines. Althera pioneers innovative value added combinations fostering benefits throughout the value chain resulting in benefits for our partners, payers, prescribers and patients particularly in heart disease, diabetes and obesity management. Althera is headquartered in Dublin, Ireland. About Jamjoom Pharma 'Jamjoom Pharmaceuticals Factory Company': Jamjoom Pharma is a leading pharmaceutical organization committed to enhancing the quality of life through the development, manufacturing, and distribution of high-quality medicines and consumer healthcare products. Headquartered in Saudi Arabia, the company was established back in 2000 and is tirelessly operating to support the Saudi Vision 2030 to reinforce the public healthcare system. With a strong focus on patient-centered care, Jamjoom Pharma serves diverse markets across Middle East & Africa, with a bold ambition for more expansion, providing effective solutions in key therapeutic areas (including ophthalmology, dermatology, cardiometabolic, gastrointestinal, and general medicine). Through its state-of-the-art facilities and established distribution channels across the MEA region and dedication to regulatory excellence, Jamjoom Pharma continues to deliver products that meet the highest standards of safety, efficacy, and quality, improving health outcomes for millions of people.


Zawya
27 minutes ago
- Zawya
CBUAE revokes licence of Al Nahdi Exchange
Abu Dhabi: The Central Bank of the UAE (CBUAE) has revoked the licence of Al Nahdi Exchange, an Exchange House operating in the UAE, and struck its name off the Register, pursuant to Article (137) of the Decretal Federal Law No. (14) of 2018 Regarding the Central Bank and Organization of Financial Institutions and Activities, and its amendments. The licence revocation was imposed based on the results of the findings of examinations conducted by the CBUAE, which revealed that the Exchange House had significant failures to comply with the Anti-Money Laundering and Combating the Financing of Terrorism and Illegal Organisations and Sanctions framework. The CBUAE, through its supervisory and regulatory mandates, endeavours to ensure that all exchange houses, their owners, and staff comply with the UAE laws, regulations and standards established by the CBUAE to maintain transparency and integrity of the exchange houses industry and safeguard the UAE financial ecosystem.